Revere Pharmaceuticals develops a drug discovery platform that utilizes in silico modeling and proprietary assays combined with high-throughput screening to identify novel inhibitors of Rac1 and Cdc42 proteins. This approach targets aberrant Rho GTPase signaling, which drives cancer progression and contributes to inadequate treatment options for various malignancies.
Funding
$6.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers are driven by aberrant Rho GTPase signaling, specifically involving Rac1 and Cdc42 proteins, leading to disease progression and limited effectiveness of existing treatments. Current therapeutic options often fail to adequately address these underlying signaling abnormalities in various malignancies.
Solution
Revere Pharmaceuticals is developing targeted therapies by inhibiting Rac1 and Cdc42 proteins, key drivers of cancer progression. Their drug discovery platform combines in silico modeling, proprietary assays, and high-throughput screening to identify novel inhibitors of Rho GTPase activation. This approach aims to create medicines that address cancers and other diseases inadequately treated with standard-of-care therapies. By focusing on small molecules that target Rho GTPase activation, Revere Pharmaceuticals seeks to deliver novel, targeted therapeutics for areas of high unmet need.
Target Audience
The primary target audience includes patients with cancers driven by aberrant Rho GTPase signaling, as well as oncologists and researchers seeking more effective treatment options for these malignancies.
Features
- In silico modeling for identifying potential drug candidates
- Proprietary assays to validate the efficacy of identified inhibitors
- High-throughput screening capabilities for efficient drug discovery
- Focus on developing small molecules to inhibit Rho GTPase activation
- Targeting Rac1 and Cdc42 proteins involved in cancer progression